Literature DB >> 31852779

Conformational Flexibility in Respiratory Syncytial Virus G Neutralizing Epitopes.

Stanislav O Fedechkin1, Natasha L George1, Ana M Nuñez Castrejon1, Joshua R Dillen1, Lawrence M Kauvar2, Rebecca M DuBois3.   

Abstract

Respiratory syncytial virus (RSV) is a top cause of severe lower respiratory tract disease and mortality in infants and the elderly. Currently, no vaccine or effective treatment exists for RSV. The RSV G glycoprotein mediates viral attachment to cells and contributes to pathogenesis by modulating host immunity through interactions with the human chemokine receptor CX3CR1. Antibodies targeting the RSV G central conserved domain are protective in both prophylactic and postinfection animal models. Here, we describe the crystal structure of the broadly neutralizing human monoclonal antibody 3G12 bound to the RSV G central conserved domain. Antibody 3G12 binds to a conformational epitope composed of highly conserved residues, explaining its broad neutralization activity. Surprisingly, RSV G complexed with 3G12 adopts a distinct conformation not observed in previously described RSV G-antibody structures. Comparison to other structures reveals that the RSV G central conserved domain is flexible and can adopt multiple conformations in the regions flanking the cysteine noose. We also show that restriction of RSV G flexibility with a proline mutation abolishes binding to antibody 3G12 but not antibody 3D3, which recognizes a different conformation of RSV G. Our studies provide new insights for rational vaccine design, indicating the importance of preserving both the global structural integrity of antigens and local conformational flexibility at antigenic sites, which may elicit a more diverse antibody response and broader protection against infection and disease.IMPORTANCE Respiratory syncytial virus (RSV) causes severe respiratory infections in infants, young children, and the elderly, and currently, no licensed vaccine exists. In this study, we describe the crystal structure of the RSV surface glycoprotein G in complex with a broadly neutralizing human monoclonal antibody. The antibody binds to RSV G at a highly conserved region stabilized by two disulfide bonds, but it captures RSV G in a conformation not previously observed, revealing that this region is both structured and flexible. Importantly, our findings provide insight for the design of vaccines that elicit diverse antibodies, which may provide broad protection from infection and disease.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  X-ray crystallography; broadly neutralizing antibodies; protein structure-function; respiratory syncytial virus

Mesh:

Substances:

Year:  2020        PMID: 31852779      PMCID: PMC7158734          DOI: 10.1128/JVI.01879-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  75 in total

1.  Coot: model-building tools for molecular graphics.

Authors:  Paul Emsley; Kevin Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-11-26

2.  Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera.

Authors:  Joan O Ngwuta; Man Chen; Kayvon Modjarrad; M Gordon Joyce; Masaru Kanekiyo; Azad Kumar; Hadi M Yassine; Syed M Moin; April M Killikelly; Gwo-Yu Chuang; Aliaksandr Druz; Ivelin S Georgiev; Emily J Rundlet; Mallika Sastry; Guillaume B E Stewart-Jones; Yongping Yang; Baoshan Zhang; Martha C Nason; Cristina Capella; Mark E Peeples; Julie E Ledgerwood; Jason S McLellan; Peter D Kwong; Barney S Graham
Journal:  Sci Transl Med       Date:  2015-10-14       Impact factor: 17.956

3.  Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.

Authors:  Jason S McLellan; Marie Pancera; Chris Carrico; Jason Gorman; Jean-Philippe Julien; Reza Khayat; Robert Louder; Robert Pejchal; Mallika Sastry; Kaifan Dai; Sijy O'Dell; Nikita Patel; Syed Shahzad-ul-Hussan; Yongping Yang; Baoshan Zhang; Tongqing Zhou; Jiang Zhu; Jeffrey C Boyington; Gwo-Yu Chuang; Devan Diwanji; Ivelin Georgiev; Young Do Kwon; Doyung Lee; Mark K Louder; Stephanie Moquin; Stephen D Schmidt; Zhi-Yong Yang; Mattia Bonsignori; John A Crump; Saidi H Kapiga; Noel E Sam; Barton F Haynes; Dennis R Burton; Wayne C Koff; Laura M Walker; Sanjay Phogat; Richard Wyatt; Jared Orwenyo; Lai-Xi Wang; James Arthos; Carole A Bewley; John R Mascola; Gary J Nabel; William R Schief; Andrew B Ward; Ian A Wilson; Peter D Kwong
Journal:  Nature       Date:  2011-11-23       Impact factor: 49.962

4.  Antibody Recognition of Disordered Antigens.

Authors:  Christopher A MacRaild; Jack S Richards; Robin F Anders; Raymond S Norton
Journal:  Structure       Date:  2015-12-17       Impact factor: 5.006

5.  Structures of respiratory syncytial virus G antigen bound to broadly neutralizing antibodies.

Authors:  Stanislav O Fedechkin; Natasha L George; Jacob T Wolff; Lawrence M Kauvar; Rebecca M DuBois
Journal:  Sci Immunol       Date:  2018-03-09

6.  Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses.

Authors:  Jennifer Harcourt; Rene Alvarez; Les P Jones; Christine Henderson; Larry J Anderson; Ralph A Tripp
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

7.  Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection.

Authors:  L K Hallak; P L Collins; W Knudson; M E Peeples
Journal:  Virology       Date:  2000-06-05       Impact factor: 3.616

8.  PHENIX: a comprehensive Python-based system for macromolecular structure solution.

Authors:  Paul D Adams; Pavel V Afonine; Gábor Bunkóczi; Vincent B Chen; Ian W Davis; Nathaniel Echols; Jeffrey J Headd; Li-Wei Hung; Gary J Kapral; Ralf W Grosse-Kunstleve; Airlie J McCoy; Nigel W Moriarty; Robert Oeffner; Randy J Read; David C Richardson; Jane S Richardson; Thomas C Terwilliger; Peter H Zwart
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-01-22

9.  Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein.

Authors:  G W Wertz; P L Collins; Y Huang; C Gruber; S Levine; L A Ball
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  6 in total

1.  Immunogenicity and inflammatory properties of respiratory syncytial virus attachment G protein in cotton rats.

Authors:  Margaret E Martinez; Cristina Capella Gonzalez; Devra Huey; Mark E Peeples; Douglas McCarty; Stefan Niewiesk
Journal:  PLoS One       Date:  2021-02-18       Impact factor: 3.240

2.  Structure-Based Design and Antigenic Validation of Respiratory Syncytial Virus G Immunogens.

Authors:  Ana M Nuñez Castrejon; Sara M O'Rourke; Lawrence M Kauvar; Rebecca M DuBois
Journal:  J Virol       Date:  2022-03-10       Impact factor: 5.103

3.  Temporal dynamics of RSV shedding and genetic diversity in adults during the COVID-19 pandemic in a French hospital, early 2021.

Authors:  Romain Coppée; Houssem Redha Chenane; Antoine Bridier-Nahmias; Colas Tcherakian; Emilie Catherinot; Gilles Collin; Samuel Lebourgeois; Benoit Visseaux; Diane Descamps; Marc Vasse; Eric Farfour
Journal:  Virus Res       Date:  2022-09-28       Impact factor: 6.286

Review 4.  Sendai Virus-Vectored Vaccines That Express Envelope Glycoproteins of Respiratory Viruses.

Authors:  Charles J Russell; Julia L Hurwitz
Journal:  Viruses       Date:  2021-05-29       Impact factor: 5.048

5.  Learning from the past: development of safe and effective COVID-19 vaccines.

Authors:  Shan Su; Lanying Du; Shibo Jiang
Journal:  Nat Rev Microbiol       Date:  2020-10-16       Impact factor: 78.297

Review 6.  Functional Features of the Respiratory Syncytial Virus G Protein.

Authors:  Larry J Anderson; Samadhan J Jadhao; Clinton R Paden; Suxiang Tong
Journal:  Viruses       Date:  2021-07-01       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.